Fri, 27 Nov 2020

EastWest Bioscience Announces Shares for Debt Settlement

ACCESSWIRE
18 Nov 2020, 09:02 GMT+10

VANCOUVER, BC / ACCESSWIRE / November 17, 2020 / EastWest Bioscience Inc. (the 'Company' or 'EastWest') (TSXV:EAST) announces the issuance of 613,467 common shares at a price of CDN $0.05 per common share to an arm's length service provider for settlement in respect of financial consulting services (the 'Consultant') provided to the Company. The transaction with the Consultant was in the normal course of business and the consideration provided was agreed to by the Company and the Consultant.

The Company intends to move forward with the transaction above and the said shares will be issued only after all necessary approvals are obtained.

The common shares issued pursuant to this transaction are subject to TSX Venture Exchange approval and a statutory four-month hold period in accordance with applicable securities laws.

About EastWest Bioscience Inc.
EastWest is a vertically integrated wellness company with the infrastructure to become a global giant in the Hemp & CBD consumer health market. Since it was founded in 2016, EastWest continues to grow as a high-quality producer, manufacturer and distributor of multiple lines of premium health and hemp products. EastWest currently has more than 200+ NPN's in its stable of products. EastWest's Hemp consumer product lines are divided into four distinct brands: 1) Natural Advancement - natural biopharmaceutical health supplements; 2) Earth's Menu - all-natural hemp superfoods; 3) Natural Pet Science - pet food and pet supplements; and 4) ChanvreHemp - all-natural health and beauty products.

In Canada, EastWest has a 34,000 Sq. Ft, Health Canada-licensed, GMP (Good Manufacturing Practices) - certified manufacturing facility and produces premium nutraceutical brands, offering natural products for a preventive care lifestyle. EastWest and Benchmark Botanicals (BBT-CSE) also have a Joint Venture Intent to accelerate acquisition of Processor, Analytical and Research and Development licenses under the Cannabis Act in EastWest's Penticton facility. These three classes of the Cannabis Act license will allow Benchmark and EastWest to build out an extensive extraction, laboratory, and research facility at EastWest's Health Canada Certified facility.

In the USA, EastWest USA has a Joint Venture with Azema Sciences, securing for EastWest first rights on Azema's output of bulk CBD and finished CBD products manufactured, and which are ready for sale in the USA and globally. EastWest Science USA ('EastWest USA'), EastWest's US operating division, will be the preferred distributor for Azema's finished goods. These finished products will include CBD creams, tinctures and salves which are products not currently in EastWest's catalogue. Additionally, EastWest will have first right of refusal to all potential opportunities relating to Azema's Kentucky based CBD processing facility. EastWest currently has TSX Approval for sale of its consumer products in 21 US States.

ON BEHALF OF THE BOARD OF DIRECTORS OF EASTWEST BIOSCIENCE INC.

Rodney Gelineau
Co-Founder, Chief Executive Officer and Director

For Further Information:
Company Website: www.eastwestbioscience.com

Contact:
Rodney Gelineau
1-800-409-1930
investors@eastwestscience.com.

NEITHER THE TSX VENTURE EXCHANGE NOR ITS REGULATION SERVICES PROVIDER (AS THAT TERM IS DEFINED IN THE POLICIES OF THE TSX VENTURE EXCHANGE) ACCEPTS RESPONSIBILITY FOR THE ADEQUACY OR ACCURACY OF THIS RELEASE.

CAUTIONARY STATEMENT REGARDING FORWARD-LOOKING INFORMATION: This news release includes certain 'forward-looking statements' under applicable Canadian securities legislation. Forward-looking statements include, but are not limited to, statements with respect to the matters disclosed herein. Forward-looking statements are necessarily based upon a number of estimates and assumptions that, while considered reasonable, are subject to known and unknown risks, uncertainties, and other factors which may cause the actual results and future events to differ materially from those expressed or implied by such forward-looking statements. Such factors include, but are not limited to: general business, economic, competitive, political and social uncertainties; and delay or failure to receive board, shareholder or regulatory approvals. There can be no assurance that such statements will prove to be accurate, as actual results and future events could differ materially from those anticipated in such statements. Accordingly, readers should not place undue reliance on forward-looking statements. The Corporation disclaims any intention or obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise, except as required by law.

SOURCE: EastWest BioScience Group



View source version on accesswire.com:
https://www.accesswire.com/617228/EastWest-Bioscience-Announces-Shares-for-Debt-Settlement

More Calgary News

Access More

Sign up for Calgary News

a daily newsletter full of things to discuss over drinks.and the great thing is that it's on the house!